The anti-VEGF (vascular endotholelial growth factor) antibody, bevacizumab, is in clinical testing for the treatment of gliomas with promising results. However, it is quickly becoming apparent that evaluation of response, using standard measures such as enhancing tumor volume or the extent of T2-weighted abnormalities on MRI, are often unreliable. In this study of recurrent high-grade glioma patients, treated with bevacizumab plus irinotecan, we demonstrate that DSC-derived measures of relative cerebral blood volume (rCBV) while similar to standard MRI for predicting response are much more reliable, early predictors of treatment failure and disease progression compared to standard MRI methods of evaluation
BackgroundDiffusion-weighted imaging has shown initial promise for evaluating response to bevacizuma...
BackgroundEvidence from single and multicenter phase II trials have suggested diffusion MRI is a pre...
BACKGROUND:Antiangiogenic therapies for glioblastoma (GBM) such as bevacizumab (BVZ), have been unab...
BackgroundDynamic susceptibility contrast (DSC)-MRI is a well-established perfusion MR imaging techn...
Bevacizumab is thought to normalize tumor vasculature and restore the blood-brain barrier, decreasin...
BACKGROUND: To assess whether the early monitoring of the effects of bevacizumab in patients with r...
Bevacizumab is a novel treatment for the recurrent high-grade gliomas (rHGG). However, only a subset...
Perfusion weighted imaging (PWI) can be used to measure key aspects of tumor vascularity in vivo and...
Bevacizumab is a therapeutic drug used in treatment of recurrent glioblastoma to inhibit angiogenesi...
Bevacizumab is a therapeutic drug used in treatment of recurrent glioblastoma to inhibit angiogenesi...
Perfusion weighted imaging (PWI) can be used to measure key aspects of tumor vascularity in vivo and...
PurposeTo evaluate a leakage correction algorithm for T1 and T2* artifacts arising from contrast age...
Magnetic resonance imaging (MRI) plays an integral role in the diagnosis and monitoring of gliomas. ...
textabstractBackground. The current method for assessing progressive disease (PD) in glioblastoma is...
Intuitively it seems a “killer app ” for perfusion imaging (Table 1) would be its use as an early ma...
BackgroundDiffusion-weighted imaging has shown initial promise for evaluating response to bevacizuma...
BackgroundEvidence from single and multicenter phase II trials have suggested diffusion MRI is a pre...
BACKGROUND:Antiangiogenic therapies for glioblastoma (GBM) such as bevacizumab (BVZ), have been unab...
BackgroundDynamic susceptibility contrast (DSC)-MRI is a well-established perfusion MR imaging techn...
Bevacizumab is thought to normalize tumor vasculature and restore the blood-brain barrier, decreasin...
BACKGROUND: To assess whether the early monitoring of the effects of bevacizumab in patients with r...
Bevacizumab is a novel treatment for the recurrent high-grade gliomas (rHGG). However, only a subset...
Perfusion weighted imaging (PWI) can be used to measure key aspects of tumor vascularity in vivo and...
Bevacizumab is a therapeutic drug used in treatment of recurrent glioblastoma to inhibit angiogenesi...
Bevacizumab is a therapeutic drug used in treatment of recurrent glioblastoma to inhibit angiogenesi...
Perfusion weighted imaging (PWI) can be used to measure key aspects of tumor vascularity in vivo and...
PurposeTo evaluate a leakage correction algorithm for T1 and T2* artifacts arising from contrast age...
Magnetic resonance imaging (MRI) plays an integral role in the diagnosis and monitoring of gliomas. ...
textabstractBackground. The current method for assessing progressive disease (PD) in glioblastoma is...
Intuitively it seems a “killer app ” for perfusion imaging (Table 1) would be its use as an early ma...
BackgroundDiffusion-weighted imaging has shown initial promise for evaluating response to bevacizuma...
BackgroundEvidence from single and multicenter phase II trials have suggested diffusion MRI is a pre...
BACKGROUND:Antiangiogenic therapies for glioblastoma (GBM) such as bevacizumab (BVZ), have been unab...